Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
Purpose. There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2022-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/8262787 |
| _version_ | 1826992724224507904 |
|---|---|
| author | Lisa M. Hess Yongmei Chen Paolo B. Abada Heiko Konig Richard A. Walgren |
| author_facet | Lisa M. Hess Yongmei Chen Paolo B. Abada Heiko Konig Richard A. Walgren |
| author_sort | Lisa M. Hess |
| collection | DOAJ |
| description | Purpose. There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns, and clinical outcomes using a real-world database to evaluate how MCL is currently managed post-cBTKi therapy in the U.S. Methods. A large, deidentified U.S. electronic medical record (EMR) oncology database (ConcertAI) with data from January 2011 to July 2021 was utilized for this study. Eligible patients were adults with MCL who had received at least one cBTKi. Descriptive statistics were used to evaluate patient characteristics and treatment patterns. Time-to-event real-world outcomes of duration of therapy, time to next treatment discontinuation, and overall survival was evaluated using the Kaplan–Meier method. Results. A total of 946 patients met eligibility criteria. Of these, 739 (78.1%) discontinued cBTKi treatment before the end of the follow-up period, while the remaining 207 (21.9%) were still receiving cBTKi therapy at the end of the follow-up period. Among those who had discontinued the cBTKi, 352 (47.6%, 352/739) received at least one subsequent (post-cBTKi) treatment. The median duration of the immediate post-cBTKi therapy was 2.6 months (n = 352). Among the 739 patients who discontinued cBTKi treatment, the median time from cBTKi discontinuation to next treatment discontinuation or death was 3.9 months and the median overall survival was 10.3 months. Conclusions. This study demonstrates the poor outcomes experienced by patients after cBTKi therapy. There is an urgent need for safe and effective treatments for patients with recurrent or progressive MCL. |
| first_indexed | 2024-04-11T00:16:32Z |
| format | Article |
| id | doaj.art-846c07e29adc4058a73f27dbca339d6d |
| institution | Directory Open Access Journal |
| issn | 1687-9112 |
| language | English |
| last_indexed | 2025-02-18T08:53:51Z |
| publishDate | 2022-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj.art-846c07e29adc4058a73f27dbca339d6d2024-11-02T23:56:37ZengHindawi LimitedAdvances in Hematology1687-91122022-01-01202210.1155/2022/8262787Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records StudyLisa M. Hess0Yongmei Chen1Paolo B. Abada2Heiko Konig3Richard A. Walgren4Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyPurpose. There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns, and clinical outcomes using a real-world database to evaluate how MCL is currently managed post-cBTKi therapy in the U.S. Methods. A large, deidentified U.S. electronic medical record (EMR) oncology database (ConcertAI) with data from January 2011 to July 2021 was utilized for this study. Eligible patients were adults with MCL who had received at least one cBTKi. Descriptive statistics were used to evaluate patient characteristics and treatment patterns. Time-to-event real-world outcomes of duration of therapy, time to next treatment discontinuation, and overall survival was evaluated using the Kaplan–Meier method. Results. A total of 946 patients met eligibility criteria. Of these, 739 (78.1%) discontinued cBTKi treatment before the end of the follow-up period, while the remaining 207 (21.9%) were still receiving cBTKi therapy at the end of the follow-up period. Among those who had discontinued the cBTKi, 352 (47.6%, 352/739) received at least one subsequent (post-cBTKi) treatment. The median duration of the immediate post-cBTKi therapy was 2.6 months (n = 352). Among the 739 patients who discontinued cBTKi treatment, the median time from cBTKi discontinuation to next treatment discontinuation or death was 3.9 months and the median overall survival was 10.3 months. Conclusions. This study demonstrates the poor outcomes experienced by patients after cBTKi therapy. There is an urgent need for safe and effective treatments for patients with recurrent or progressive MCL.http://dx.doi.org/10.1155/2022/8262787 |
| spellingShingle | Lisa M. Hess Yongmei Chen Paolo B. Abada Heiko Konig Richard A. Walgren Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study Advances in Hematology |
| title | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study |
| title_full | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study |
| title_fullStr | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study |
| title_full_unstemmed | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study |
| title_short | Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study |
| title_sort | outcomes among patients with mantle cell lymphoma post covalent btk inhibitor therapy in the united states a real world electronic medical records study |
| url | http://dx.doi.org/10.1155/2022/8262787 |
| work_keys_str_mv | AT lisamhess outcomesamongpatientswithmantlecelllymphomapostcovalentbtkinhibitortherapyintheunitedstatesarealworldelectronicmedicalrecordsstudy AT yongmeichen outcomesamongpatientswithmantlecelllymphomapostcovalentbtkinhibitortherapyintheunitedstatesarealworldelectronicmedicalrecordsstudy AT paolobabada outcomesamongpatientswithmantlecelllymphomapostcovalentbtkinhibitortherapyintheunitedstatesarealworldelectronicmedicalrecordsstudy AT heikokonig outcomesamongpatientswithmantlecelllymphomapostcovalentbtkinhibitortherapyintheunitedstatesarealworldelectronicmedicalrecordsstudy AT richardawalgren outcomesamongpatientswithmantlecelllymphomapostcovalentbtkinhibitortherapyintheunitedstatesarealworldelectronicmedicalrecordsstudy |